

# The Development of an Interactive Visual Tool to Communicate the Burden of Atopic Dermatitis in Finland

Iida Peltonen, Jaakko Kopra, Mari Renlund

AbbVie Oy, Helsinki, Finland

## OBJECTIVE

The objective was to develop an interactive visual tool to communicate the burden of atopic dermatitis (AD) to healthcare professionals (HCPs) and other stakeholders in Finland using the results from recent Finnish ReloAD-FIN registry study by AbbVie Oy. The goal of the project is to improve the standards of care in AD in Finland.

## CONCLUSIONS

An interactive visual tool was developed to communicate the burden of AD in Finland to HCPs and other stakeholders.

The tool visualizes the number of patients with mild, moderate and severe AD in national and regional level as well as the burden of various AD-related comorbidities.

The tool enables effective and tailored communication on the ReloAD-FIN study<sup>1</sup> data about the burden of AD in Finland to local healthcare providers and demonstrates the need to improve the standards of care.

AbbVie Oy funded this project and participated in the design of the interactive visual tool. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. The authors thank Heini Honkanen, Johanna Viskula and Katerina Gävanger of Medafcon Oy, Espoo, for the development of the tool, and Doctor Ville Kiiski, Helsinki, the ReloAD-FIN investigator.

Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: IP, JK and MR are employees of AbbVie and may or may not own AbbVie stock.

The data from ReloAD-FIN registry study have been previously presented in a publication Kiiski et al. (2023) Effect of Disease Severity on Comorbid Conditions in Atopic Dermatitis: Nationwide Registry-Based Investigation in Finnish Adults. Acta Dermato-Venereologica, 103, adv00882. <https://doi.org/10.2340/actadv.v103.4447>

For additional information or to obtain a PDF of this poster



Scan QR code or utilize the following link to download an electronic version of this presentation and other scientific presentations by AbbVie Oy in ISPOR Europe 2023:

[abbvie.ie/ISPOR2023-abbvieposters](https://abbvie.ie/ISPOR2023-abbvieposters)  
QR code expiration: 15.11.2024

To submit a medical question, please visit [www.abbviemedinfo.com](http://www.abbviemedinfo.com)

## INTRODUCTION


### Atopic dermatitis (AD)

Atopic dermatitis is highly prevalent in Finland, but the burden of the disease is not fully understood, and patients are often undertreated.

The recent ReloAD-FIN registry study<sup>1</sup> by AbbVie Oy shows an increased morbidity of patients with severe AD, regarding infectious, dermatological, psychiatric, metabolic, and musculoskeletal diseases and lymphomas.

## RESULTS


**Figure 1. The Interactive Visual Tool shows the number of patients with mild, moderate and severe AD in Finland regionally by University Hospital Districts**




### Prevalence of mild, moderate and severe AD in Finland

- In total, 53,046, 46,296 and 24,696 patients with mild, moderate and severe AD respectively, were identified in the ReloAD-FIN registry study<sup>1</sup>
- In addition to the total number of patients by severity, the Visual Tool shows the distribution of patients regionally

**Figure 2. In The Visual Tool it is possible to choose a region of interest to investigate the detailed patient numbers by disease severity leading to increased understanding of the burden of AD**



**Figure 3. The Interactive Visual Tool enables the examination of different types of AD-related comorbidities and their prevalence by the severity grade of AD**



### AD-related comorbidities

- Severe AD increases the risk of infectious, dermatological, mental health, metabolic, and musculoskeletal diseases and lymphomas<sup>1</sup>
- In the Visual Tool, the comorbidities can be viewed as easy-to-read graphs that visualize the prevalence of different types of morbidities according to AD severity

**Figure 4. AD-related comorbidities are listed in the Visual Tool in more detail by disease severity, ICD-10 diagnosis code and prevalence**



<sup>1</sup> Kiiski et al. (2023) Effect of Disease Severity on Comorbid Conditions in Atopic Dermatitis: Nationwide Registry-Based Investigation in Finnish Adults. Acta Dermato-Venereologica, 103, adv00882. <https://doi.org/10.2340/actadv.v103.4447>